High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma

Gherardo Mazziotti, AM Formenti, S Frara, R Olivetti, G Banfi, M Memo, R Maroldi, Raffaele Giubbini, A Giustina

Research output: Contribution to journalArticle

Abstract

Context: Bone loss and nonvertebral fractures have been reported in patients with differentiated thyroid carcinoma (DTC) undergoing thyroid-stimulating hormone (TSH) suppressive therapy. Radiological vertebral fractures (VFs) are an early and clinically crucial marker of bone fragility.Objective and Design: A cross-sectional study to evaluate the prevalence and determinants of radiological VFs in women receiving l-thyroxine (L-T4) therapy for DTC.Patients and Interventions: A total of 179 consecutive women (median age, 59 years; n = 178 postmenopausal) who had undergone thyroidectomy for DTC and were currently receiving L-T4 were evaluated for radiological VFs and bone mineral density (BMD). There were three TSH target levels [1.0 mU/L, group 3 (n = 46)].Results: VFs were found in 51 patients (28.5%), with significantly (P <0.001) higher prevalence in group 1 (44.6%) as compared with group 2 (24.0%) and group 3 (4.3%). VF prevalence was not significantly different among patients in group 1 with normal BMD, osteopenia, or osteoporosis, whereas in groups 2 and 3, VFs were more frequent in patients with osteoporosis than in those with either osteopenia or normal BMD. In the whole population, VFs were significantly and independently associated with TSH level
Original languageEnglish
Pages (from-to)956-964
Number of pages9
JournalThe Journal of clinical endocrinology and metabolism
Volume103
Issue number3
DOIs
Publication statusPublished - 2018

Fingerprint Dive into the research topics of 'High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma'. Together they form a unique fingerprint.

  • Cite this